Collegium Pharmaceutical, Inc.

Valuation Analysis

About the Company

Collegium Pharmaceutical, Inc. en bref

Collegium Pharmaceutical, Inc. (COLL) is currently trading at 29,27 € with a market capitalization of 949 M €. The trailing P/E ratio stands at 16.28x, with a forward P/E of 4.41x. The 52-week range spans from 25,47 € to 44,32 €; the current price is 34% below the yearly high. Year-over-year revenue growth stands at +8.9%. The net profit margin stands at 9.41%.

💰 Dividende

Collegium Pharmaceutical, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

6 analystes évaluent Collegium Pharmaceutical, Inc. (COLL) au consensus : None. L'objectif de cours moyen est de 47,41 €, soit un potentiel de +62% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 39,27 € à 52,36 €.

Collegium Pharmaceutical, Inc. : la thèse d'investissement en détail

Collegium Pharmaceutical, Inc. (COLL) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 89.17%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 27.41% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

Le scénario baissier

The debt-to-equity ratio of 297.57% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn. Short interest sits at 20.88% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

The EV/EBITDA multiple of 3.84x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 4.41x is meaningfully below the trailing 16.28x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 62% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (20.88%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Collegium Pharmaceutical, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.